Millennium Management LLC acquired a new stake in Crispr Therapeutics AG (NASDAQ:CRSP) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 106,538 shares of the company’s stock, valued at approximately $4,366,000. Millennium Management LLC owned 0.19% of Crispr Therapeutics as of its most recent SEC filing.
A number of other large investors have also added to or reduced their stakes in the business. Benjamin Edwards Inc. increased its stake in Crispr Therapeutics by 96.4% during the 2nd quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock worth $26,000 after acquiring an additional 268 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Crispr Therapeutics by 13.6% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,870 shares of the company’s stock valued at $118,000 after purchasing an additional 343 shares during the last quarter. Traynor Capital Management Inc. boosted its stake in Crispr Therapeutics by 5.8% during the 3rd quarter. Traynor Capital Management Inc. now owns 6,845 shares of the company’s stock valued at $280,000 after purchasing an additional 375 shares during the last quarter. Commonwealth Equity Services LLC boosted its stake in shares of Crispr Therapeutics by 2.2% in the 3rd quarter. Commonwealth Equity Services LLC now owns 18,201 shares of the company’s stock worth $746,000 after buying an additional 386 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. boosted its stake in shares of Crispr Therapeutics by 7.1% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 7,019 shares of the company’s stock worth $331,000 after buying an additional 467 shares during the last quarter. Hedge funds and other institutional investors own 49.82% of the company’s stock.
CRSP has been the topic of a number of analyst reports. Roth Capital boosted their target price on shares of Crispr Therapeutics from $65.00 to $100.00 in a report on Tuesday, November 19th. Canaccord Genuity raised their target price on shares of Crispr Therapeutics from $72.00 to $80.00 and gave the company a “positive” rating in a research note on Wednesday, November 20th. Needham & Company LLC reiterated a “buy” rating and set a $84.00 price target on shares of Crispr Therapeutics in a research note on Monday, December 23rd. ValuEngine raised shares of Crispr Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, November 1st. Finally, Goldman Sachs Group upped their price target on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 19th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and fourteen have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $71.38.
In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total value of $390,000.00. Following the sale, the director now owns 7,500 shares of the company’s stock, valued at approximately $390,000. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the transaction, the president now directly owns 33,618 shares of the company’s stock, valued at $2,353,260. The disclosure for this sale can be found here. Insiders have sold 56,118 shares of company stock valued at $3,620,760 over the last three months. Insiders own 21.40% of the company’s stock.
Shares of NASDAQ:CRSP opened at $66.01 on Friday. The business’s 50 day moving average is $64.60 and its 200-day moving average is $50.48. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $3.68 billion, a PE ratio of -19.19 and a beta of 3.31. Crispr Therapeutics AG has a 1-year low of $26.00 and a 1-year high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, October 28th. The company reported $2.40 EPS for the quarter, topping analysts’ consensus estimates of ($0.95) by $3.35. The company had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. On average, sell-side analysts predict that Crispr Therapeutics AG will post 0.65 EPS for the current year.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: How prevalent are 12b-1 fees?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.